Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Makes A United Bid For COVID-19 Vaccines

International Procurement Proposal Opens Door For Global Solidarity

Executive Summary

A new EU-wide strategy on procuring potential COVID-19 vaccines through advance purchase agreements has been launched, replacing earlier fragmented efforts by some member states. 

You may also be interested in...



EU Prepares Ground For Deployment Of COVID-19 Vaccines

With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.

No Blanket Immunity For COVID-19 Vaccine Liabilities, Says EU

As the race to develop COVID-19 vaccines continues, EU member states are ready to financially cover certain of the companies’ risks, but not to change the rules on liability. Transparency proponents are calling for all contracts on vaccine purchases to be made public.

EFPIA Rejects EU Calls To Relax IP Protections

State-imposed mechanisms such as compulsory licensing will discourage rather than encourage investment in R&D, says Europe’s research-based industry. It has also dismissed suggestions that Europe is too dependent on API supplies from third countries.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS142401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel